We are Sorry, This Page doesn't Exist
Hedge Funds Are Dumping Sangamo Therapeutics, Inc. (SGMO)
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so p.....»»
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2019 Results - Earnings Call Transcript
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2019 Results - Earnings Call Transcript.....»»
Sangamo Therapeutics (SGMO) Investor Presentation - Slideshow
Sangamo Therapeutics (SGMO) Investor Presentation - Slideshow.....»»
Sangamo Therapeutics Becomes Oversold (SGMO)
Dividend Channel.....»»
First Week of May 2020 Options Trading For Sangamo Therapeutics (SGMO)
Stock Options Channel.....»»
Why Is Sangamo Therapeutics Moving?
Shares of Sangamo Therapeutics Inc (NASDAQ: SGMO) are higher by 7.6% Monday afternoon. read more.....»»
Sangamo Therapeutics (SGMO) Shares Cross Above 200 DMA
Market News Video.....»»
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2019 Results - Earnings Call Transcript
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2019 Results - Earnings Call Transcript.....»»
Sangamo Therapeutics, Inc. (SGMO) Sangamo Clinical Development Update Conference Call (Transcript)
Sangamo Therapeutics, Inc. (SGMO) Sangamo Clinical Development Update Conference Call (Transcript).....»»
51 Stocks Moving In Tuesday"s Mid-Day Session
Gainers Sangamo Therapeutics Inc (NASDAQ: SGMO) shares climbed 35.1 percent to $12.87 after the company announced positive Phase 1/2 interim data for its investigational Hemophilia gene therapy. read more.....»»
Sangamo Therapeutics" (SGMO) CEO Sandy Macrae on Q1 2018 Results - Earnings Call Transcript
Sangamo Therapeutics" (SGMO) CEO Sandy Macrae on Q1 2018 Results - Earnings Call Transcript.....»»
Sangamo Announces TxCell Acquisition, Patient Dosing In SB-318
Sangamo Therapeutics Inc (NASDAQ: SGMO) announced Monday it would acquire TxCell for about €72 million to complement its ex vivo gene editing program. read more.....»»
Sangamo Therapeutics (SGMO) Updates On Proposed Acquisition Of TxCell - Slideshow
Sangamo Therapeutics (SGMO) Updates On Proposed Acquisition Of TxCell - Slideshow.....»»
Sangamo Therapeutics" (SGMO) CEO Sandy Macrae on Q2 2018 Results - Earnings Call Transcript
Sangamo Therapeutics" (SGMO) CEO Sandy Macrae on Q2 2018 Results - Earnings Call Transcript.....»»
Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 8% in Session
Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes. Sangamo Therapeutics, Inc. SGMO was a big mover last session, as the compa.....»»
Sangamo Shares Sink After Data Release For Gene Editing Product Candidate
Sangamo Therapeutics Inc (NASDAQ: SGMO) shares opened sharply lower Wednesday following the release of clinical trial data for its pipeline candidate SB-913. read more.....»»
Sangamo Therapeutics, Inc. (SGMO) CEO Alexander Macrae on Q3 2018 Results - Earnings Call Transcript
Sangamo Therapeutics, Inc. (SGMO) CEO Alexander Macrae on Q3 2018 Results - Earnings Call Transcript.....»»
Sangamo"s Shares Drop on Rating Downgrade, Pipeline Woes
Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development. Sangamo Therap.....»»
Sangamo Fails To Impress Investors With Genome Editing Studies
Sangamo Therapeutics Inc (NASDAQ: SGMO) shares have come under pressure following an announcement concerning interim results from two genome editing studies presented at the WORLDSymposium 2019Â i read more.....»»
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2018 Results - Earnings Call Transcript
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2018 Results - Earnings Call Transcript.....»»